Orphan nuclear receptors in drug discovery.
Orphan nuclear receptors provide a unique resource for uncovering novel regulatory systems that impact human health and also provide drug targets for a variety of human diseases. Ligands of nuclear receptors have been used in several important therapeutic areas, such as breast cancers, skin disorders and diabetes. Orphan nuclear receptors, therefore, represent a tremendous opportunity in understanding and treating human diseases. Here, I highlight recent advances in the use of orphan nuclear receptors and their potential as targets for drug discovery in diabetes, obesity, neurodegenerative diseases and other related disorders.
Shi
Yanhong
Y
Division of Neurosciences, Center for Gene Expression and Drug Discovery, Beckman Research Institute of City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA. yshi@coh.org
D000818:Animals; D004268:DNA-Binding Proteins / Q000187:drug effects / Q000235:genetics; D015195:Drug Design; D006801:Humans; D008024:Ligands; D057094:Nuclear Receptor Subfamily 1, Group F, Member 1; D057126:Nuclear Receptor Subfamily 4, Group A, Member 2; D057093:Orphan Nuclear Receptors; D047492:Peroxisome Proliferator-Activated Receptors / Q000187:drug effects / Q000235:genetics; D010600:Pharmacology / Q000639:trends*; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects* / Q000235:genetics / Q000502:physiology*; D015534:Trans-Activators / Q000187:drug effects / Q000235:genetics; D014157:Transcription Factors / Q000187:drug effects / Q000235:genetics
D004268:DNA-Binding Proteins; D008024:Ligands; C088601:NR2E1 protein, human; C539882:NR4A2 protein, human; D057094:Nuclear Receptor Subfamily 1, Group F, Member 1; D057126:Nuclear Receptor Subfamily 4, Group A, Member 2; D057093:Orphan Nuclear Receptors; D047492:Peroxisome Proliferator-Activated Receptors; D018160:Receptors, Cytoplasmic and Nuclear; D015534:Trans-Activators; D014157:Transcription Factors